Kazuhiko Nakagawa

Kazuhiko Nakagawa

UNVERIFIED PROFILE

Are you Kazuhiko Nakagawa?   Register this Author

Register author
Kazuhiko Nakagawa

Kazuhiko Nakagawa

Publications by authors named "Kazuhiko Nakagawa"

Are you Kazuhiko Nakagawa?   Register this Author

100Publications

2483Reads

23Profile Views

[fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification.

Int J Cancer 2019 Dec 24;145(12):3414-3424. Epub 2019 May 24.

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.32408DOI Listing
December 2019

A Case of Metastatic Malignant Breast Adenomyoepithelioma With a Codon-61 Mutation of HRAS.

Clin Breast Cancer 2019 Oct 20;19(5):e589-e592. Epub 2019 Jun 20.

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.05.001DOI Listing
October 2019

Clinical and immune profiling for cancer of unknown primary site.

J Immunother Cancer 2019 Sep 13;7(1):251. Epub 2019 Sep 13.

Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohno-higashi, Osaka-Sayama, Osaka, 589-8511, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0720-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743146PMC
September 2019

Combination therapy with PD-1 or PD-L1 inhibitors for cancer.

Int J Clin Oncol 2019 Sep 23. Epub 2019 Sep 23.

Department of Medical Oncology, Faculty of Medicine, Kindai University, 377-2 Ohno-higashi, Osaka-Sayama, Osaka, 589-8511, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-019-01548-1DOI Listing
September 2019

Reply to A.-M. Conway et al.

J Clin Oncol 2019 Aug 18;37(23):2090. Epub 2019 Jun 18.

Hidetoshi Hayashi, MD, PhD; Kazuto Nishio, PhD; and Kazuhiko Nakagawa, MD, Kindai University, Osaka-Sayama, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.00767DOI Listing
August 2019

Effects of dose modifications on the safety and efficacy of dacomitinib for mutation-positive non-small-cell lung cancer.

Future Oncol 2019 Aug 17;15(24):2795-2805. Epub 2019 Jul 17.

Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, 510080, PR China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2019-0299DOI Listing
August 2019

Successful long-term treatment of non-small cell lung cancer positive for rearrangement with pemetrexed.

Onco Targets Ther 2019 8;12:5355-5358. Epub 2019 Jul 8.

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka 589-8511, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S211582DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6625745PMC
July 2019

Management of common adverse events related to first-line dacomitinib use in mutation-positive non-small-cell lung cancer: a pooled safety analysis.

Future Oncol 2019 May 6;15(13):1481-1491. Epub 2019 Mar 6.

State Key Laboratory of South China, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, PR China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0944DOI Listing
May 2019

New Era for Next-Generation Sequencing in Japan.

Cancers (Basel) 2019 May 28;11(6). Epub 2019 May 28.

Department of Genome Biology, Kindai University Faculty of Medicine, 377-2 Ohno-higashi, Osaka-Sayama, Osaka 589-8511, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11060742DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627271PMC
May 2019

A Phase II Study of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer who Responded to Prior PD-1/L1 Inhibitors: West Japan Oncology Group 9616L (WJOG9616L).

Clin Lung Cancer 2019 03 11;20(2):139-141. Epub 2018 Dec 11.

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.001DOI Listing
March 2019

Safety and Efficacy of Alectinib in a Patient With Advanced NSCLC Undergoing Hemodialysis.

J Thorac Oncol 2019 03;14(3):e50-e52

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.11.012DOI Listing
March 2019

Dual blockade of EGFR tyrosine kinase using osimertinib and afatinib eradicates EGFR‑mutant Ba/F3 cells.

Oncol Rep 2019 Feb 22;41(2):1059-1066. Epub 2018 Nov 22.

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka‑Sayama, Osaka 589‑8511, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/or.2018.6881DOI Listing
February 2019

First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive Mutation-Positive Non-Small Cell Lung Cancer?

Int J Mol Sci 2019 Jan 3;20(1). Epub 2019 Jan 3.

Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohno-higashi, Osaka-Sayama, Osaka 589-8511, Japan.

View Article

Download full-text PDF

Source
http://www.mdpi.com/1422-0067/20/1/146
Publisher Site
http://dx.doi.org/10.3390/ijms20010146DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337322PMC
January 2019

Nivolumab-Induced Hemophilia A Presenting as Gastric Ulcer Bleeding in a Patient With NSCLC.

J Thorac Oncol 2018 12 12;13(12):e239-e241. Epub 2018 Jul 12.

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.06.024DOI Listing
December 2018

Gankyrin Contributes to Tumorigenesis and Chemoresistance in Sporadic Colorectal Cancer.

Digestion 2019 4;100(3):192-200. Epub 2018 Dec 4.

Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000494969DOI Listing
December 2018

Induction Chemoradiotherapy (50 Gy), Followed by Resection, for Stage IIIA-N2 Non-Small Cell Lung Cancer.

Ann Thorac Surg 2018 10 8;106(4):1018-1024. Epub 2018 Jun 8.

Department of Thoracic Surgery, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.athoracsur.2018.05.027DOI Listing
October 2018

An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors.

Cancer Chemother Pharmacol 2018 09 10;82(3):511-519. Epub 2018 Jul 10.

Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka, 589-8511, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-018-3618-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105164PMC
September 2018

Nivolumab-induced acute granulomatous tubulointerstitial nephritis in a patient with gastric cancer.

Invest New Drugs 2018 08 6;36(4):726-731. Epub 2018 Apr 6.

Department of Nephrology, Kindai University Faculty of Medicine, 377-2 Ohno-higashi, Osaka-sayama, Osaka, 589-8511, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-018-0596-7DOI Listing
August 2018

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.

J Clin Oncol 2018 08 16;36(22):2251-2258. Epub 2018 May 16.

Benjamin J. Solomon, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Dong-Wan Kim, Seoul National University Hospital, Seoul, Republic of Korea; Yi-Long Wu, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou; Tony S. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; Kazuhiko Nakagawa, Kindai University Faculty of Medicine, Osaka, Japan; Tarek Mekhail, Florida Hospital, Orlando, FL; Enriqueta Felip, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Federico Cappuzzo, Azienda Unità Sanitaria Locale Della Romagna, Ravenna; Jolanda Paolini and Tiziana Usari, Pfizer Oncology, Milan, Italy; Yiyun Tang and Keith D. Wilner, Pfizer Oncology, La Jolla, CA; and Fiona Blackhall, Manchester University, and Christie Hospital National Health Service Foundation Trust, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.4794DOI Listing
August 2018

Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.

J Clin Oncol 2018 08 4;36(22):2244-2250. Epub 2018 Jun 4.

Tony S. Mok, State Key Laboratory of South China, Chinese University of Hong Kong, Hong Kong; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun; Xiangdong Zhou, First Affiliated Hospital of Third Military Medical University, Chongqing; Yi-Long Wu, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China; Ki Hyeong Lee, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea; Kazuhiko Nakagawa, Kindai University Hospital, Osaka; Seiji Niho, National Cancer Center Hospital East, Kashiwa, Japan; Min Lee, SFJ Asia Pacific, Singapore; Rolf Linke, SFJ Pharmaceuticals Group, Pleasanton, CA; Rafael Rosell, Catalan Institute of Oncology, Barcelona; Jesus Corral, Hospital Universitario Virgen del Rocio, Seville, Spain; Maria Rita Migliorino, Pulmonary Oncology Unit, San Camillo-Forlanini Hospital, Rome, Italy; Adam Pluzanski, The Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland; Eric I. Sbar, Pfizer, Collegeville, PA; Tao Wang and Jane Liang White, Pfizer, Groton, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.7994DOI Listing
August 2018

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

J Clin Oncol 2018 Aug 28:JCO2018783118. Epub 2018 Aug 28.

Thanyanan Reungwetwattana, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Kazuhiko Nakagawa, Kindai University School of Medicine, Osaka; Naoyuki Nogami, National Hospital Organization Shikoku Cancer Center, Matsuyama; Isamu Okamoto, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Byoung Chul Cho, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul; Eun Kyung Cho, Gachon University Gil Medical Center, Incheon; Ki Hyeong Lee, Chungbuk National University Hospital, Cheong-ju, Republic of Korea; Manuel Cobo, Institute of Biomedical Research in Málaga, Málaga University Hospital Regional, Málaga, Spain; Alessandro Bertolini, Hospital of Sondrio, Sondrio, Italy; Sabine Bohnet, Universitätsklinik Schleswig-Holstein, Lübeck, Germany; Caicun Zhou, Pulmonary Hospital of Tongji University, Shanghai, People's Republic of China; Natasha Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Rachel Hodge, Astrid McKeown, Andrew P. Brown, and Yuri Rukazenkov, AstraZeneca, Cambridge, United Kingdom; Suresh S. Ramalingam, Winship Cancer Institute, Emory University, Atlanta, GA; and Johan Vansteenkiste, University Hospital, Katholieke Universiteit Leuven, Leuven, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.3118DOI Listing
August 2018

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer.

Cancer Res Treat 2018 Jul 6;50(3):691-700. Epub 2017 Jul 6.

State Key Laboratory of South China, Hong Kong Cancer Institute and The Chinese University of Hong Kong, Shatin, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4143/crt.2017.280DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056984PMC
July 2018

Immune-Related Adverse Events-A Novel Prediction of Nivolumab Efficacy?-Reply.

JAMA Oncol 2018 07;4(7):1017-1018

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2018.0751DOI Listing
July 2018

Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.

Lung Cancer 2018 07 17;121:37-40. Epub 2018 Apr 17.

Thoracic Center, St. Luke's International Hospital, Chuo-ku, Tokyo 104-8560 Japan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2018.04.015DOI Listing
July 2018

In Reply.

J Thorac Oncol 2018 05;13(5):e86-e87

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.02.003DOI Listing
May 2018

Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring fusions: a phase I study.

Oncotarget 2018 May 4;9(34):23729-23737. Epub 2018 May 4.

Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Minami-ku, Fukuoka-shi, Fukuoka 811-1395, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.25263DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955103PMC
May 2018

Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of or .

Oncotarget 2018 Apr 20;9(30):21132-21140. Epub 2018 Apr 20.

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka 589-8511, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.24958DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940408PMC
April 2018

Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort.

Lung Cancer 2018 03 9;117:14-19. Epub 2018 Jan 9.

Department of Medical Oncology, Izumi Municipal Hospital, 4-10-10 Fuchu, Izumi, 594-0071, Japan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2018.01.005DOI Listing
March 2018

[Result of Clinical Trials of Ceritinib in Patients with ALK-Rearranged Non-Small-Cell Lung Cancer and Management of the Adverse Events].

Gan To Kagaku Ryoho 2018 Feb;45(2):257-264

Dept. of Thoracic Oncology, Hyogo Cancer Center.

View Article

Download full-text PDF

Source
February 2018

Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses.

J Clin Oncol 2017 Dec 2;35(36):4027-4034. Epub 2017 Oct 2.

Tony S.K. Mok, The Chinese University of Hong Kong, Prince of Wales Hospital, Sha Tin, Hong Kong, Special Administrative Region, People's Republic of China; Yi-Long Wu and Jin-Ji Yang, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou; Jie Wang, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing; You Lu, Sichuan University, Sichuan; Xiaojin Shi, AstraZeneca, Shanghai, People's Republic of China; James Chih-Hsin Yang, The National Taiwan University Hospital and College of Medicine, Taipei, Taiwan, Republic of China; Sang-We Kim, University of Ulsan College of Medicine; Myung-Ju Ahn, Sungkyunkwan University School of Medicine, Seoul, South Korea; Kazuhiko Nakagawa, Kindai University; Shinji Atagi, Kinkichuo Chest Medical Center, Osaka, Japan; Santiago Ponce, Hospital Universitario 12 de Octubre, Madrid, Spain; Yuri Rukazenkov, AstraZeneca, Cambridge; Vincent Haddad, AstraZeneca, Royston, United Kingdom; Kenneth S. Thress, AstraZeneca, Waltham, MA; and Jean-Charles Soria, Gustave Roussy Cancer Campus and University Paris-Sud, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.9250DOI Listing
December 2017

Prognostic Impact of Minimal Pericardial Effusion in Patients With Advanced Non-small-cell Lung Cancer.

Clin Lung Cancer 2017 11 10;18(6):e449-e455. Epub 2017 May 10.

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2017.05.011DOI Listing
November 2017

Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.

J Clin Oncol 2017 Nov 13;35(32):3662-3670. Epub 2017 Sep 13.

Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan University Cancer Center, Taipei City, Peoples Republic of China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.7297DOI Listing
November 2017

DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.

Int J Cancer 2017 10 12;141(8):1682-1689. Epub 2017 Jul 12.

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayamashi, Osaka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.30870DOI Listing
October 2017

Incidence of carnitine deficiency in patients with cancer pain: A pilot study.

Mol Clin Oncol 2017 Mar 7;6(3):331-333. Epub 2017 Feb 7.

Department of Psychosomatic Medicine, Kindai University Faculty of Medicine, Osaka 589-8511, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/mco.2017.1159DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403195PMC
March 2017

Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR.

ESMO Open 2017 7;2(Suppl 1):e000104. Epub 2017 Mar 7.

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama , Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2016-000104DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559906PMC
March 2017